We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.00 | 10.30 | 10.80 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -2.72 | 30.27M |
TIDMC4XD
RNS Number : 5136U
C4X Discovery Holdings PLC
29 July 2020
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Cancellation and Regrant of Existing Share Options
2 9 July 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it is to cancel and reissue a number of unexpired options to subscribe for its ordinary shares of 0.1p each ("Ordinary Shares") which have been held by various employees and the Directors of the Company since their grant between 2015 and 2018 (the "Regrant").
The Regrant brings the strike price of the share options into line with the current market price of the Company's shares and should now deliver a viable incentive and reward package to the employees and Directors of the Company.
The Regrant options have an exercise price of 16p, being the closing price of the Ordinary Shares on 28 July 2020. The options can be exercised at any time between 3 years and 10 years of them being granted.
The share option holdings by the Directors of C4X Discovery before and after the Regrant are summarised as follows:
Options before Regrant Options following Regrant Expiry Date 08-Jun-15 08-Dec-15 23-Nov-16 01-Feb-17 15-May-18 28-Jul-20 -------------- ---------- ---------- ---------- ---------- ---------- -------- ---------- -------- Director Strike Price GBP1.00 GBP0.77 GBP1.05 GBP0.91 GBP0.892 Total GBP0.16 Total pence per Share -------------- ---------- ---------- ---------- ---------- ---------- -------- ---------- -------- Chief Clive Executive Dix Officer 20,000 125,000 0 0 50,000 195,000 195,000 195,000 -------------- ---------- ---------- ---------- ---------- ---------- -------- ---------- -------- Chief Brad Financial Hoy Officer 0 0 300,000 0 50,000 350,000 350,000 350,000 -------------- ---------- ---------- ---------- ---------- ---------- -------- ---------- -------- Chief Craig Scientific Fox Officer 150,000 0 50,000 50,000 250,000 250,000 250,000 -------------- ---------- ---------- ---------- ---------- ---------- -------- ---------- -------- TOTAL OPTIONS OUTSTANDING 170,000 125,000 300,000 50,000 150,000 795,000 795,000 795,000 ---------- ---------- ---------- ---------- ---------- -------- ---------- --------
- Ends -
Contacts
C4X Discovery Holdings Mo Noonan, Communications +44 (0)787 6444977 Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) +44 (0)20 7886 2500 James Stearns (Corporate Broking) C4X Discovery Media - Consilium Strategic Communications Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
For additional information please go to: www.c4xdiscovery.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCSEFFDUESSEIW
(END) Dow Jones Newswires
July 29, 2020 09:54 ET (13:54 GMT)
1 Year C4x Discovery Chart |
1 Month C4x Discovery Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions